AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026